National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

hydroxyurea
A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:HYD
Hydroxycarbamide
Hydurea
US brand names:Droxia
Hydrea
Foreign brand names:Litalir
Onco-Carbide
Oxeron
Syrea
Abbreviation:HU
Code names:SQ-1089
WR 83799



Previous:Hydrea, Hydrocortone, hydromorphone hydrochloride, Hydrostat, hydroxychloroquine
Next:Hymorphan, HyperAcute-Lung Cancer Vaccine, Hyperacute-Pancreatic Cancer Vaccine, hyperbaric oxygen, hyperimmune bovine colostrum

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov